Research Institute of Hematology and Blood Transfusion
About Research Institute of Hematology and Blood Transfusion
The Tashkent Medical Academy or TMA is a public undergraduate and graduate medical school and research university based in Tashkent, Uzbekistan. The TMA is one of the oldest and largest Universities in Uzbekistan, the center of medical education and research in medicine and Life Sciences in the Republic.
- Top Sponsors
- Top Collaborators
- Trials By Phase
- Recruitment Status
- Top Conditions
- Intervention Types
- Top Intervention Names
- Trials By Gender
Lead Sponsor
# Trials
Clinical Trials at Research Institute of Hematology and Blood Transfusion
During the past decade, Research Institute of Hematology and Blood Transfusion conducted 1 clinical trials. In the 10-year time frame, 1 clinical trials started and 0 clinical trials were completed, i.e. on
average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 0 clinical trials were completed. i.e. 0%
of trials that started reached the finish line.
Trials List
Trail ID
Brief Title
Start Date
Completion Date
Status
Enrollment
Brentuximab Vedotin and Nivolumab With or Without Ipilimumab in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma
2014-01-24
2025-03-20
Recruiting
146
Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia
2013-12-23
2023-07-01
Active, not recruiting
488
Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial)
2014-08-18
2026-10-10
Active, not recruiting
450
Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)
2014-08-18
Recruiting
8,300
Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)
2014-08-18
2036-05-01
Recruiting
168
Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma
2015-07-13
2023-10-02
Active, not recruiting
300
A Phase II/III Trial of Nivolumab, Ipilimumab, and GM-CSF in Patients With Advanced Melanoma
2015-09-10
2033-06-30
Recruiting
600
Platinum in Treating Patients With Residual Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy
2015-04-29
2031-03-29
Active, not recruiting
415
Clinical Trials Sponsors and Collaborators
Clinical Trials Conditions at Research Institute of Hematology and Blood Transfusion
According to Clinical.Site data, the most researched conditions in "Research Institute of Hematology and Blood Transfusion" are
"Childhood Acute Lymphoblastic Leukemia" (2 trials). Many other conditions were trialed in "Research Institute of Hematology and Blood Transfusion" in a lesser frequency.
Clinical Trials Intervention Types at Research Institute of Hematology and Blood Transfusion
Most popular intervention types in "Research Institute of Hematology and Blood Transfusion" are "Drug" (2 trials) and "Radiation" (1 trials). Other intervention types were less common.
The name of intervention was led by "Daunorubicin" (2 trials), "Bortezomib" (1 trials), "Cranial irradiation" (1 trials), "Dexamethasone" (1 trials) and "Dexamethasone continuous" (1 trials). Other intervention names were less common.
Clinical Trials Genders at Research Institute of Hematology and Blood Transfusion
The vast majority of trials in "Research Institute of Hematology and Blood Transfusion" are
2 trials for "All" genders.
Clinical Trials Status at Research Institute of Hematology and Blood Transfusion
Currently, there are NaN active trials in "Research Institute of Hematology and Blood Transfusion".
undefined are not yet recruiting,
1 are recruiting,
undefined are Active, not recruiting,
and undefined are Enrolling by invitation.
In total, there were undefined completed trials in Research Institute of Hematology and Blood Transfusion,
undefined suspended trials,
and undefined terminated clinical trials to date.
Out of the total trials that were conducted in Research Institute of Hematology and Blood Transfusion, 0 "Phase 1"
clinical trials were conducted, 0 "Phase 2" clinical
trials and 0 "Phase 3" clinical trials were conducted as
well. "Phase 4" trials included 0 trials, and there were
also 2 trials that are defined as “Not Applicable".